Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
This article was originally published in The Tan Sheet
Executive Summary
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk-management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb